Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors Exhibit Bactericidal Activity against Planktonic and Biofilm Staphylococcus aureus In Vitro

被引:2
作者
Chen, Anna [1 ]
Dellos-Nolan, Sheri [1 ]
Lu, Yanran [2 ]
West, Jason S. [2 ]
Wozniak, Daniel J. [1 ,3 ]
Mitton-Fry, Mark J. [2 ]
机构
[1] Ohio State Univ, Coll Med, Microbial Infect & Immun, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Arts & Sci, Dept Microbiol, Columbus, OH USA
基金
美国国家卫生研究院;
关键词
biofilm; Staphylococcus; topoisomerase; METHICILLIN-RESISTANT; COMBINATION; VANCOMYCIN; SYNERGY; EPIDEMIOLOGY; INFECTIONS; INSIGHTS;
D O I
10.1128/spectrum.02056-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The development of novel treatments for Staphylococcus aureus infections remains a high priority worldwide. We previously reported compounds 0147 and 0186, novel bacterial topoisomerase inhibitors (NBTIs) with potent antibacterial activity against S. aureus, including methicillin-resistant S. aureus. Here, we further investigated the in vitro activity of 0147 and 0186 against S. aureus ATCC 29213. Both compounds demonstrated bactericidal activity against planktonic and biofilm S. aureus, which then translated into significant inhibition of biofilm formation. Combinations of NBTIs and glycopeptides yielded indifferent interactions against planktonic S. aureus, but several had synergistic effects against S. aureus biofilms. This work reinforces the potential of NBTIs as future therapeutics for S. aureus infections.
引用
收藏
页数:9
相关论文
共 47 条
[11]  
Clinical Laboratory Standards Institute, 2018, M07- Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, V11th
[12]   Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors [J].
D'Atanasio, Noemi ;
de Joannon, Alessandra Capezzone ;
Di Sante, Laura ;
Mangano, Giorgina ;
Ombrato, Rosella ;
Vitiello, Marco ;
Bartella, Cristina ;
Magaro, Gabriele ;
Prati, Federica ;
Milanese, Claudio ;
Vignaroli, Carla ;
Di Giorgio, Francesco Paolo ;
Tongiani, Serena .
PLOS ONE, 2020, 15 (02)
[13]   Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms [J].
Dall, G. F. ;
Tsang, S-T J. ;
Gwynne, P. J. ;
MacKenzie, S. P. ;
Simpson, A. H. R. W. ;
Breusch, S. J. ;
Gallagher, M. P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (07) :1830-1840
[14]   Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections [J].
Davis, J. S. ;
Van Hal, S. ;
Tong, S. Y. C. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (01) :3-16
[15]   When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing [J].
Doern, Christopher D. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (12) :4124-4128
[16]   NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-negative Bacteria and In Vivo Efficacy [J].
Dougherty, Thomas J. ;
Nayar, Asha ;
Newman, Joseph V. ;
Hopkins, Sussie ;
Stone, Gregory G. ;
Johnstone, Michele ;
Shapiro, Adam B. ;
Cronin, Mark ;
Reck, Folkert ;
Ehmann, David E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) :2657-2664
[17]   Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria [J].
Flamm, R. K. ;
Farrell, D. J. ;
Rhomberg, P. R. ;
Scangarella-Oman, N. E. ;
Sader, H. S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (07)
[18]   Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase [J].
Gibson, Elizabeth G. ;
Bax, Ben ;
Chan, Pan F. ;
Osheroff, Neil .
ACS INFECTIOUS DISEASES, 2019, 5 (04) :570-581
[19]   Review: Staphylococcus aureus and MRSA in cystic fibrosis [J].
Goss, Christopher H. ;
Muhlebach, Marianne S. .
JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (05) :298-306
[20]  
Innovotech, 2021, MBEC ASS PROC MAN HI